Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders

Ghasemian, Majid; Rajabibazl, Masoumeh; Sahebi, Unes; Sadeghi, Samira; Maleki, Reza; Hashemnia, Veys; Mirfakhraie, Reza

doi:10.1186/s12935-022-02633-8

Cited by 16 publications

(16 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, MIR4435-2HG , which is a long non-coding RNA, is also known as LncRNA-AWPPH , LINC00978 , or MORRBID ( Ghasemian et al, 2022 ). Interestingly, MIR4435-2HG overexpression has previously been associated with hypomethylation in gliomas ( Zhong et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL

Torres-Llanos,

Zabaleta,

Cruz-Rodriguez

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Although B-cell acute lymphoblastic leukemia (B-cell ALL) survival rates have improved in recent years, Hispanic children continue to have poorer survival rates. There are few tools available to identify at the time of diagnosis whether the patient will respond to induction therapy. Our goal was to identify predictive biomarkers of treatment response, which could also serve as prognostic biomarkers of death, by identifying methylated and differentially expressed genes between patients with positive minimal residual disease (MRD+) and negative minimal residual disease (MRD-).Methods: DNA and RNA were extracted from tumor blasts separated by immunomagnetic columns. Illumina MethlationEPIC and mRNA sequencing assays were performed on 13 bone marrows from Hispanic children with B-cell ALL. Partek Flow was used for transcript mapping and quantification, followed by differential expression analysis using DEseq2. DNA methylation analyses were performed with Partek Genomic Suite and Genome Studio. Gene expression and differential methylation were compared between patients with MRD−/− and MRD+/+ at the end of induction chemotherapy. Overexpressed and hypomethylated genes were selected and validated by RT-qPCR in samples of an independent validation cohort. The predictive ability of the genes was assessed by logistic regression. Survival and Cox regression analyses were performed to determine the association of genes with death.Results:DAPK1, BOC, CNKSR3, MIR4435-2HG, CTHRC1, NPDC1, SLC45A3, ITGA6, and ASCL2 were overexpressed and hypomethylated in MRD+/+ patients. Overexpression was also validated by RT-qPCR. DAPK1, BOC, ASCL2, and CNKSR3 can predict refractoriness, but MIR4435-2HG is the best predictor. Additionally, higher expression of MIR4435-2HG increases the probability of non-response, death, and the risk of death. Finally, MIR4435-2HG overexpression, together with MRD+, are associated with poorer survival, and together with overexpression of DAPK1 and ASCL2, it could improve the risk classification of patients with normal karyotype.Conclusion:MIR4435-2HG is a potential predictive biomarker of treatment response and death in children with B-cell ALL.

show abstract

Section: Discussionmentioning

confidence: 99%

MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL

Torres-Llanos,

Zabaleta,

Cruz-Rodriguez

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…In this study, we used TCGA-HNSCC datasets and clinical samples to verify the high expression of MIAT in HNSCC tissues, but the high expression of MIAT was beneficial to the prognosis of patients, which may be a compensatory increase in tumor to increase the infiltration of tumor immune cells and improve the anti-tumor immunity of HNSCC patients. MIR4435-2HG has also been shown to be up-regulated in gastric cancer, hepatocellular cancer, colorectal cancer, ovarian carcinoma, and renal cell carcinoma, which can promote the expression of downstream target genes through sponging miRNAs, inhibit tumor cell apoptosis, and enhance cell proliferation, invasion, migration, and EMT [60]. Wang et al found that mir4435-2Hg was highly expressed in HNSCC tissues, and in vitro and in vivo experiments verified that MIR4435-2HG promoted HNSCC cell proliferation, migration, invasion, and tumor growth by regulating the miR-383-5P/RBM3 axis [61].…”

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma

Cai

Liang

Jiang

et al. 2022

Cancers

View full text Add to dashboard Cite

At present, the prognostic value of N6-methyladenosine (m6A)-related enhancer RNAs (eRNAs) for head and neck squamous cell carcinoma (HNSCC) still remains unclear. Our study aims to explore the prognostic value of m6A-related eRNAs in HNSCC patients and their potential significance in immune infiltration and immunotherapy. We constructed a 5 m6A-related eRNAs risk model from The Cancer Genome Atlas (TCGA) HNSCC dataset, using univariate and multivariate Cox and least absolute shrinkage and selection operator (LASSO) regression analysis. Based on the SRAMP website and in vitro experiments, it was verified that these 5 m6A-related eRNAs had m6A sites, the expression of which was regulated by corresponding m6A regulators. Moreover, we constructed a nomogram base on 5 m6A-related eRNAs and confirmed the consistency and robustness of an internal TCGA testing set. Further analysis found that the risk score was positively associated with low overall survival (OS), tumor cell metastasis, metabolic reprogramming, low immune surveillance, lower expression of immune-related genes, and higher expression of targeted genes. Finally, we verified that silencing MIR4435-2HG inhibited HNSCC cell migration and invasion. This study contributes to the understanding of the characteristics of m6A-related eRNAs in HNSCC and provides a reference for effective immunotherapy and targeted therapy.

show abstract

“…The self‐renewal capacity of cancerous cells was impaired after silencing SAMMSON, and its ability was recovered after SAMMSON overexpression 25 . EZH2 is a primary component of polycomb repressive complex 2 (PPRC2) 2 . CTNNBIP1 protein is a physiological negative regulator of the Wnt pathway that prevents interaction between CTNNB1 and TCF/LEF complex and inhibits Wnt signalling activation 33 .…”

Section: Sammson and Tumorigenesismentioning

confidence: 99%

The oncogenic role of SAMMSON lncRNA in tumorigenesis: A comprehensive review with especial focus on melanoma

Ghasemian,

Babaahmadi‐Rezaei,

Khedri

et al. 2023

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

LncRNA Survival Associated Mitochondrial Melanoma Specific Oncogenic Non‐coding RNA (SAMMSON) is located on human chromosome 3p13, and its expression is upregulated in several tumours, including melanoma, breast cancer, glioblastoma and liver cancer and has an oncogenic role in malignancy disorders. It has been reported that SAMMSON impacts metabolic regulation, cell proliferation, apoptosis, EMT, drug resistance, invasion and migration. Also, SAMMSON is involved in regulating several pathways such as Wnt, MAPK, PI3K, Akt, ERK and p53. SAMMSON is considered a potential diagnostic and prognostic biomarker in several types of cancer and a suitable therapeutic target. In addition, the highly expressed SAMMSON is closely associated with clinicopathological features of various cancers. SAMMSON has a significant role in regulating epigenetic processes by regulating histone protein or the status of DNA methylation. Herein for the first time, we comprehensively summarized the currently available SAMMSON, molecular regulatory pathways, and clinical significance. We believe that clarifying all the molecular aspects of this lncRNA can be a good guide for cancer studies in the future.

show abstract

Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders

Cited by 16 publications

References 87 publications

MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL

MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL

Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma

The oncogenic role of SAMMSON lncRNA in tumorigenesis: A comprehensive review with especial focus on melanoma

Contact Info

Product

Resources

About